Skip to main content

Day: April 7, 2022

Webinar: Piezo Motion’s Miniature Motors Are Driving Next Generation of Medical Devices

On April 21, Dr. Mark Broderick will discuss how Piezo Motion is revolutionizing the miniature-motor industry and providing viable solutions in high-tech industries LAKEWOOD RANCH, Fla., April 07, 2022 (GLOBE NEWSWIRE) — via InvestorWire — On April 21, Piezo Motion, a Brain Scientific (OTCQB:BRSF) company, will host a webinar discussing its miniature precision motors and the new opportunities they create for medical devices and high-tech industries. Dr. Mark Broderick, Ph.D., will analyze the stability and accuracy of Piezo Motion’s multifaceted rotary and linear miniature motors, designed specifically for medical device manufacturers requiring improved speed, size and accuracy. “Our motion solutions are enabling a new generation of high tech and medical devices,” said Hassan Kotob, chairman and CEO of Brain Scientific. “Traditionally,...

Continue reading

Enphase Energy Expands Battery Storage in Nevada

FREMONT, Calif., April 07, 2022 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, announced today that installers of Enphase® products in Nevada have seen growing deployments of the Enphase Energy System, powered by IQ™ Microinverters and IQ™ Batteries. Residential battery capacity is growing in Nevada, with forecasts estimating deployments will multiply nearly six-fold by 2026, according to the most recent U.S. Energy Storage Monitor report from the Energy Storage Association and Wood Mackenzie. In addition, Nevada homeowners can now choose to install Enphase’s revolutionary IQ8™ Microinverters. IQ8-based systems can provide Sunlight Backup during an outage, even without a battery. For homeowners who...

Continue reading

Bionano Genomics Announces Release of Version 6.2 of its NxClinical Software with Significant New Capabilities for Cancer Research Applications Including HRD Analysis

Version includes a powerful capability for genomic scar analysis for assessments of homologous recombination deficiency (HRD) that provides an efficient, consistent approach for analysis of tumor biomarkers used in pharmacogenomics and other cancer research SAN DIEGO, April 07, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the launch of an integrated genomic scar analysis for homologous recombination deficiency (HRD) in the version 6.2 software release of NxClinical. This feature provides a comprehensive, consistent, and automated analysis of biomarkers from next-generation sequencing (NGS) and microarray data...

Continue reading

Rogue Station Companies Inc./Everdime Inc. Adds Seasoned High-Level Banking CEO to its Board of Directors

Grant MacKenzie currently serves as president of Peoples Bank of Canada Sheridan, Wyoming, April 07, 2022 (GLOBE NEWSWIRE) — Rogue Station Companies, Inc./Everdime Inc. (OTC Pink: RGST) is extremely pleased to announce the addition of Grant MacKenzie to its Board of Directors. Mr. MacKenzie is the President and CEO of Peoples Group, Peoples Trust Company and Peoples Bank of Canada. He has more than 40 years of executive and financial management experience in the Banking/Financial Services industries. Peoples Group was founded in 1985 and is based in Vancouver, Canada. They have over 300 employees in Canada and manage more than $19 billion in assets. Mr. MacKenzie commented, “Sandor’s plan to position Everdime in NFT development and trading within the Crypto space is smart and on track. NFTs and Meta Verse are the new...

Continue reading

Acuity Brands Appoints Sach Sankpal as Senior Vice President, Growth and Transformation

Sach Sankpal Acuity Brands Appoints Sach Sankpal, pictured here, as Senior Vice President, Growth and TransformationAtlanta, April 07, 2022 (GLOBE NEWSWIRE) — Acuity Brands, Inc. (NYSE: AYI) (“Acuity” or the “Company”), a market-leading industrial technology company, today announced the appointment of Sach Sankpal as Senior Vice President, Growth and Transformation, and a member of the executive leadership team. Sankpal will lead the technology organization, deploy the Company’s Better.Smarter.Faster. operating system, and direct integration efforts for future Acuity mergers and acquisitions. He brings extensive experience leading successful business transformations in the industrial sector.   “We are excited to have Sach on our team,” said Neil Ashe, Chairman, President and CEO, Acuity Brands,...

Continue reading

NV5 to Host 2022 Investor Day on Thursday, May 26th

HOLLYWOOD, Fla., April 07, 2022 (GLOBE NEWSWIRE) — NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of compliance, technology, engineering, and environmental consulting solutions, announced today that it will host an Investor Day on Thursday, May 26, 2022 at 10:00 am Central Time. The Investor Day will be held at The Glen Club in Glenview, IL during the first round of the NV5 Invitational, an annual event on the PGA TOUR’s Korn Ferry Tour schedule. The 2022 Investor Day will present NV5’s strategic plan to continue driving growth and margins that exceed the industry average. NV5 Chairman and CEO, Dickerson Wright, and Chief Financial Officer, Edward Codispoti, will host the event followed by a question and answer session.   Investor Day will conclude with demonstrations of the technologies that are expected...

Continue reading

Pactiv Evergreen Inc. Schedules First Quarter 2022 Financial Results

LAKE FOREST, Ill., April 07, 2022 (GLOBE NEWSWIRE) — Pactiv Evergreen (NASDAQ: PTVE) today announced the following details for its first quarter 2022 earnings release and teleconference call.Earnings release:   Wednesday, May 4, 2022, after market close     Webcast and Teleconference:   Thursday, May 5, 2022 at 8:00 a.m. ET.     Pactiv Evergreen Participants:   Michael King, CEO    Michael Ragen, CFO    Dhaval Patel, SVP, Investor Relations & StrategyParticipants may access the live webcast on the Company’s Investor Relations website at https://investors.pactivevergreen.com/news-events/events-presentations. The call may also be accessed by dialing 1-844-825-9789 from the U.S. or 1-412-317-5180 internationally and using access code 10165348. About Pactiv Evergreen Inc. Pactiv Evergreen Inc. is one of...

Continue reading

Claudia Fan Munce Joins Arteris IP Board of Directors

Veteran executive, Stanford lecturer and public company board member brings decades of relevant international corporate experience to Arteris IPClaudia Fan Munce New Arteris IP Board MemberCAMPBELL, Calif., April 07, 2022 (GLOBE NEWSWIRE) — Arteris IP (NASDAQ: AIP), a leading provider of system IP consisting of network-on-chip (NoC) interconnect and IP deployment software that accelerate system-on-chip (SoC) creation, today announced that Claudia Fan Munce will join Arteris IP’s Board of Directors and will commence her service at the company’s May 2022 board and committee meetings.   Claudia Fan Munce’s distinguished 30-year career at IBM culminated with her role as Vice President of Corporate Development. Throughout her tenure at IBM, she held various positions, including executive roles in engineering, IP licensing, and IBM...

Continue reading

Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET

CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the details of its webcast to discuss updated clinical data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors and relapsed/refractory acute myeloid leukemia on April 8, 2022, at 1:15 p.m. ET. In addition to members of the Rubius management team, Alexander I. Spira, M.D., Ph.D., FACP​, Co-Director, Virginia Cancer Specialists Research Institute, Director, Thoracic and Phase 1 Program and RTX-240 clinical investigator, will join...

Continue reading

Manhattan Associates recognized as a Leader in the 2022 Gartner® Magic Quadrant™ for Transportation Management Systems

Positioned as a Magic Quadrant Leader for the fourth consecutive year, Manhattan Associates offers the only cloud-native, 100 percent microservices TMS ATLANTA, April 07, 2022 (GLOBE NEWSWIRE) — Manhattan Associates Inc. (NASDAQ: MANH), a global leader in supply chain commerce solutions, today announced that, for the fourth year in a row, it has been named a Leader in Gartner Inc. Magic Quadrant™ for Transportation Management Systems.1 Today’s logistics networks are incredibly complex and transportation management systems are under tremendous pressure to perform more shipments with fewer resources. Manhattan Active® Transportation Management was redesigned and rebuilt last year with the industry’s fastest and smartest shipping optimization engine to create the industry’s most technologically advanced transportation planning and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.